Aimei Health Technology Adjourns Extraordinary General Meeting

Aimei Health Technology Co., Ltd (NASDAQ: AFJKU) recently announced the postponement of its Extraordinary General Meeting held on February 4, 2025. The meeting failed to reach a quorum required for conducting business, prompting the Company to reschedule the event.

As per the provisions outlined in Article 12.2 of the Company’s Amended and Restated Articles of Association, in the event of a lacking quorum within 15 minutes of the meeting’s designated start time, the meeting must be adjourned. The adjournment has been scheduled for February 5, 2025, at 4:00 p.m. Eastern Time to allow more shareholders to participate and fulfill the quorum requirement.

The adjourned Extraordinary General Meeting is set to take place both physically at the offices of the Company’s legal advisors, Hunter Taubman Fischer & Li LLC, and virtually online. Shareholders will have the opportunity to cast their votes during the reconvened meeting in the same manner as outlined in the proxy statement filed with the U.S. Securities and Exchange Commission on January 21, 2025, along with supplementary proxy materials dated January 30, 2025. Proxies submitted ahead of the reconvened meeting will remain valid unless revised or revoked before voting occurs.

In compliance with the Securities Exchange Act of 1934, Aimei Health Technology Co., Ltd has confirmed the authenticity of this report by the duly authorized undersigned individual, Chief Executive Officer Junheng Xie, signing off on February 4, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aimei Health Technology’s 8K filing here.

Aimei Health Technology Company Profile

Aimei Health Technology Co, Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.